Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oculis Holding AGOISE:OCS -1.10%26 PB Ratio is 2.63 as of Jul. 31, 2026. GuruFocus rates OISE:OCS with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,228 Biotechnology companies, Oculis Holding AG ranks worse than 50.08% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-31), Oculis Holding AG's share price is kr1350.00. Oculis Holding AG's Book Value per Share for the quarter that ended in Mar. 2026 was kr513.05. Hence, Oculis Holding AG's PB Ratio of today is 2.63.
The historical rank and industry rank for Oculis Holding AG's PB Ratio or its related term are showing as below:
OISE:OCS'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.72
Current: 2.72
During the past 6 years, Oculis Holding AG's highest PB Ratio was 2.72. The lowest was 0.00. And the median was 0.00.
OISE:OCS's PB Ratio is ranked worse than 50.08% of 1228
companies
in the Biotechnology industry
Industry Median: 2.705
vs OISE:OCS: 2.72
During the past 12 months, Oculis Holding AG's average Book Value Per Share Growth Rate was 125.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Oculis Holding AG PB Ratio Related Terms
Oculis Holding AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Oculis Holding AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oculis Holding AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oculis Holding AG PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oculis Holding AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Oculis Holding AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Oculis Holding AG (OISE:OCS) has a PB Ratio of 2.63 as of Jul. 31, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oculis Holding AG and its competitors. According to the industry distribution chart, Oculis Holding AG ranks #615 out of 1228 companies in the Biotechnology industry, placing it in the top 50.1%.
Is Oculis Holding AG's PB Ratio too high?
Oculis Holding AG's current PB Ratio is 2.63. The Biotechnology industry median PB Ratio is 2.71. Oculis Holding AG's value of 2.63 is 2.8% below this industry median. Based on the distribution chart, Oculis Holding AG ranks #615 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oculis Holding AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's PB Ratio compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #615 out of 1228 companies for PB Ratio. This places Oculis Holding AG in the lower half of its industry. The industry median PB Ratio is 2.71. Oculis Holding AG's value of 2.63 is 2.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.71, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oculis Holding AG's current PB Ratio of 2.63 is 2.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oculis Holding AG and its competitors. For the Biotechnology industry, the median PB Ratio is 2.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oculis Holding AG's current PB Ratio is 2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (OISE:OCS) has a current PB Ratio of 2.63. The current PB Ratio is 2.63 and 2.8% below the Biotechnology industry median of 2.71. Oculis Holding AG's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Oculis Holding AG (OISE:OCS), the current PB Ratio is 2.63 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
26GF Score
Get the complete analysis for OISE:OCS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OISE:OCS has been successfully added to your 
